When it comes to education among its residents, the Houston area lands in the bottom half of America's smartest cities. Photo by Utamaru Kido/Getty Images

Houston sits toward the back of the class when it comes to the smartest metro areas in the U.S., according to a new study.

In the study, published by personal finance website WalletHub, the Houston-The Woodlands-Sugar Land area ranks 90th among the most-educated metros. Houston trails Austin-Round Rock (No. 9) and Dallas-Fort Worth (No. 71) but outperforms San Antonio-New Braunfels (No. 106) on the 150-metro list. At the very bottom of the list are McAllen (No. 148) and Brownsville (No. 149).

Houston's ranking remains unchanged from WalletHub's 2018 study.

To determine where the most-educated Americans live, WalletHub compared the 150 largest metros across 11 metrics. That data includes the share of adults 25 and older with at least a bachelor's degree, the quality of public schools, and the gender gap in education.

Here's how Houston fared across some of the data categories (lower ranking is better):

  • No. 30 — Black-versus-white education gap
  • No. 36 — Quality of public schools
  • No. 59 — Share of adults with at least a bachelor's degree
  • No. 65 — Women-versus-men education gap
  • No. 72 — Share of adults with a graduate or professional degree
  • No. 74 — Average quality of universities
  • No. 90 — Share of adults with an associate's degree or college experience
  • No. 112 — Students enrolled in top 951 universities per capita
  • No. 135 — Share of residents with a high school diploma

The most educated metro in this year's ranking is Ann Arbor, Michigan. Visalia-Porterville, California, though, sits at the bottom of the list as the nation's least educated metro.

------

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”